Alterations in the apoptotic machinery and their potential role in anticancer drug resistance

Scott H Kaufmann, David L. Vaux

Research output: Contribution to journalArticle

237 Citations (Scopus)

Abstract

Anticancer drugs can potentially kill cells in two fundamentally different ways, by interfering with cellular processes that are essential for maintenance of viability or by triggering an endogenous physiological cell death mechanism. Apoptosis is a form of physiological cell death mediated by caspases, a unique family of intracellular cysteine proteases. Zymogen forms of these proteases are found in virtually all somatic cells, but remain latent until their activation is induced by ligation of specific cell surface receptors (the so-called 'death receptors'), by mitochondrial alterations that allow release of cytochrome c and other intermembrane components, or possibly by other mechanisms. Most anticancer drugs activate the mitochondrial pathway. This apoptotic pathway is regulated by pro- and antiapoptotic members of the Bcl-2 family of proteins. Once activated, certain caspases might also be controlled by the inhibitor of apoptosis (IAP) proteins. Alterations in apoptotic pathway components or their regulators have been detected in a variety of cancers, suggesting that loss of the ability of cells to undergo apoptosis might contribute to carcinogenesis. Because cancer therapies such as radiation, glucocorticoids, and chemotherapeutic drugs exert their beneficial effects, at least in part, by inducing apoptosis of cancer cells, the same alterations in apoptotic pathways would be predicted to contribute to resistance. A key issue is whether the direct toxic activity of these treatments is of benefit when neoplastic cells contain changes that diminish their ability to undergo apoptosis.

Original languageEnglish (US)
Pages (from-to)7414-7430
Number of pages17
JournalOncogene
Volume22
Issue number47 REV. ISS. 6
DOIs
StatePublished - Oct 20 2003

Fingerprint

Drug Resistance
Apoptosis
Caspases
Cell Death
Pharmaceutical Preparations
Inhibitor of Apoptosis Proteins
Neoplasms
Death Domain Receptors
Enzyme Precursors
Cysteine Proteases
Poisons
Cell Surface Receptors
Cytochromes c
Glucocorticoids
Ligation
Carcinogenesis
Peptide Hydrolases
Maintenance
Radiation
Proteins

Keywords

  • Apoptosis
  • Bcl-2
  • Carcinogenesis
  • Caspases
  • Drug resistance
  • IAP
  • Stress response

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. / Kaufmann, Scott H; Vaux, David L.

In: Oncogene, Vol. 22, No. 47 REV. ISS. 6, 20.10.2003, p. 7414-7430.

Research output: Contribution to journalArticle

@article{77194547bef445ea9070dc36b57fc278,
title = "Alterations in the apoptotic machinery and their potential role in anticancer drug resistance",
abstract = "Anticancer drugs can potentially kill cells in two fundamentally different ways, by interfering with cellular processes that are essential for maintenance of viability or by triggering an endogenous physiological cell death mechanism. Apoptosis is a form of physiological cell death mediated by caspases, a unique family of intracellular cysteine proteases. Zymogen forms of these proteases are found in virtually all somatic cells, but remain latent until their activation is induced by ligation of specific cell surface receptors (the so-called 'death receptors'), by mitochondrial alterations that allow release of cytochrome c and other intermembrane components, or possibly by other mechanisms. Most anticancer drugs activate the mitochondrial pathway. This apoptotic pathway is regulated by pro- and antiapoptotic members of the Bcl-2 family of proteins. Once activated, certain caspases might also be controlled by the inhibitor of apoptosis (IAP) proteins. Alterations in apoptotic pathway components or their regulators have been detected in a variety of cancers, suggesting that loss of the ability of cells to undergo apoptosis might contribute to carcinogenesis. Because cancer therapies such as radiation, glucocorticoids, and chemotherapeutic drugs exert their beneficial effects, at least in part, by inducing apoptosis of cancer cells, the same alterations in apoptotic pathways would be predicted to contribute to resistance. A key issue is whether the direct toxic activity of these treatments is of benefit when neoplastic cells contain changes that diminish their ability to undergo apoptosis.",
keywords = "Apoptosis, Bcl-2, Carcinogenesis, Caspases, Drug resistance, IAP, Stress response",
author = "Kaufmann, {Scott H} and Vaux, {David L.}",
year = "2003",
month = "10",
day = "20",
doi = "10.1038/sj.onc.1206945",
language = "English (US)",
volume = "22",
pages = "7414--7430",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "47 REV. ISS. 6",

}

TY - JOUR

T1 - Alterations in the apoptotic machinery and their potential role in anticancer drug resistance

AU - Kaufmann, Scott H

AU - Vaux, David L.

PY - 2003/10/20

Y1 - 2003/10/20

N2 - Anticancer drugs can potentially kill cells in two fundamentally different ways, by interfering with cellular processes that are essential for maintenance of viability or by triggering an endogenous physiological cell death mechanism. Apoptosis is a form of physiological cell death mediated by caspases, a unique family of intracellular cysteine proteases. Zymogen forms of these proteases are found in virtually all somatic cells, but remain latent until their activation is induced by ligation of specific cell surface receptors (the so-called 'death receptors'), by mitochondrial alterations that allow release of cytochrome c and other intermembrane components, or possibly by other mechanisms. Most anticancer drugs activate the mitochondrial pathway. This apoptotic pathway is regulated by pro- and antiapoptotic members of the Bcl-2 family of proteins. Once activated, certain caspases might also be controlled by the inhibitor of apoptosis (IAP) proteins. Alterations in apoptotic pathway components or their regulators have been detected in a variety of cancers, suggesting that loss of the ability of cells to undergo apoptosis might contribute to carcinogenesis. Because cancer therapies such as radiation, glucocorticoids, and chemotherapeutic drugs exert their beneficial effects, at least in part, by inducing apoptosis of cancer cells, the same alterations in apoptotic pathways would be predicted to contribute to resistance. A key issue is whether the direct toxic activity of these treatments is of benefit when neoplastic cells contain changes that diminish their ability to undergo apoptosis.

AB - Anticancer drugs can potentially kill cells in two fundamentally different ways, by interfering with cellular processes that are essential for maintenance of viability or by triggering an endogenous physiological cell death mechanism. Apoptosis is a form of physiological cell death mediated by caspases, a unique family of intracellular cysteine proteases. Zymogen forms of these proteases are found in virtually all somatic cells, but remain latent until their activation is induced by ligation of specific cell surface receptors (the so-called 'death receptors'), by mitochondrial alterations that allow release of cytochrome c and other intermembrane components, or possibly by other mechanisms. Most anticancer drugs activate the mitochondrial pathway. This apoptotic pathway is regulated by pro- and antiapoptotic members of the Bcl-2 family of proteins. Once activated, certain caspases might also be controlled by the inhibitor of apoptosis (IAP) proteins. Alterations in apoptotic pathway components or their regulators have been detected in a variety of cancers, suggesting that loss of the ability of cells to undergo apoptosis might contribute to carcinogenesis. Because cancer therapies such as radiation, glucocorticoids, and chemotherapeutic drugs exert their beneficial effects, at least in part, by inducing apoptosis of cancer cells, the same alterations in apoptotic pathways would be predicted to contribute to resistance. A key issue is whether the direct toxic activity of these treatments is of benefit when neoplastic cells contain changes that diminish their ability to undergo apoptosis.

KW - Apoptosis

KW - Bcl-2

KW - Carcinogenesis

KW - Caspases

KW - Drug resistance

KW - IAP

KW - Stress response

UR - http://www.scopus.com/inward/record.url?scp=0344393783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344393783&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1206945

DO - 10.1038/sj.onc.1206945

M3 - Article

C2 - 14576849

AN - SCOPUS:0344393783

VL - 22

SP - 7414

EP - 7430

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 47 REV. ISS. 6

ER -